Get the Stockscreener App
53.11
1.50%
-0.81
After Hours:
52.52
-0.59
-1.11%
Halozyme Therapeutics Inc stock is traded at $53.11, with a volume of 1.63M.
It is down -1.50% in the last 24 hours and up +2.10% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$53.92
Open:
$53.58
24h Volume:
1.63M
Relative Volume:
0.75
Market Cap:
$6.63B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
17.59
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
-1.23%
1M Performance:
+2.10%
6M Performance:
+9.28%
1Y Performance:
+6.95%
1-Day Range:
$52.96
$53.83
1-Week Range:
$52.96
$55.60
52-Week Range:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
53.11 | 6.63B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN
TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - marketscreener.com
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus
Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance
Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance
Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus
Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey
(HALO) Investment Report - news.stocktradersdaily.com
Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World
Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal
Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK
Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus
Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail
Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
Breakthrough: EU Approves 5-Minute Cancer Treatment Option Using Halozyme's Technology - Stock Titan
High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance
New Strong Buy Stocks for May 28th - The Globe and Mail
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus
Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq
Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):